Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
The drug adds a new use to its US label, but Takeda’s 2017 Ariad acquisition still looks expensive.
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
AstraZeneca's quiet, cautious work is followed by a $2bn takeover.
Three recently added trials take Merck & Co’s tally of phase 3 sacituzumab tirumotecan studies to six.
